Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Multiple Myeloma(MM)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Not Yet RecruitingNCT07537049
What this trial is testing

BR101 in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 10
Not applicableStudy completedNCT06504524
What this trial is testing

Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US

Who this might be right for
Multiple Myeloma
Pfizer 633
Not applicableStudy completedNCT05932290
What this trial is testing

Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 514
Early research (Phase 1)Ended earlyNCT04887259
What this trial is testing

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Who this might be right for
Chronic Lymphocytic LeukemiaMultiple MyelomaAcute Myeloid Leukemia
Lava Therapeutics 16
Early research (Phase 1)WithdrawnNCT02658396
What this trial is testing

GO-203-2C + Bortezomib For Relapsed Or Refractory MM

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseRefractory Multiple Myeloma
Dana-Farber Cancer Institute
Testing effectiveness (Phase 2)Looking for participantsNCT06158412
What this trial is testing

All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
The First Affiliated Hospital of Xiamen University 25
Early research (Phase 1)Study completedNCT02920697
What this trial is testing

Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Chronic Lymphocytic Leukaemia (CLL)B-Cell Non-Hodgkin Lymphoma (NHL)Multiple Myeloma (MM)
Institut de Recherches Internationales Servier 65
Early research (Phase 1)Ended earlyNCT04895410
What this trial is testing

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Who this might be right for
Multiple Myeloma
AbbVie 8
Early research (Phase 1)Study completedNCT01114282
What this trial is testing

Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM

Who this might be right for
Multiple Myeloma
Stanford University 11
Not applicableStudy completedNCT05565391
What this trial is testing

Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 508
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07107204
What this trial is testing

A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed or Refractory Hematologic MalignanciesLeukemiaLymphoma+1 more
Biotroy Therapeutics 116
Testing effectiveness (Phase 2)Looking for participantsNCT07116616
What this trial is testing

MRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc. 190
Testing effectiveness (Phase 2)Looking for participantsNCT05908409
What this trial is testing

IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

Who this might be right for
Multiple Myeloma (MM)Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedDouble Hit Lymphoma+3 more
IDP Discovery Pharma S.L. 37
Not applicableStudy completedNCT05673967
What this trial is testing

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed and Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 62
Testing effectiveness (Phase 2)Study completedNCT02384083
What this trial is testing

Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients

Who this might be right for
Multiple Myeloma
PETHEMA Foundation 47
Testing effectiveness (Phase 2)Study completedNCT01394354
What this trial is testing

Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma in Relapse
University Hospital Freiburg 34
Testing effectiveness (Phase 2)Looking for participantsNCT06627751
What this trial is testing

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

Who this might be right for
Extramedullary Disease in Multiple MyelomaRecurrent Multiple MyelomaRefractory Multiple Myeloma
Roswell Park Cancer Institute 28
Early research (Phase 1)Study completedNCT00317798
What this trial is testing

Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma

Who this might be right for
Drug/Agent Toxicity by Tissue/OrganMultiple Myeloma and Plasma Cell Neoplasm
University of Rochester 18
Early research (Phase 1)UnknownNCT05020639
What this trial is testing

TQB3820 in Patients With Hematological Malignancies

Who this might be right for
Hematological Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 116
Testing effectiveness (Phase 2)Looking for participantsNCT06196255
What this trial is testing

Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)

Who this might be right for
Multiple Myeloma
Xuzhou Medical University 20
Next Page